Bariatric Surgery

Bariatric surgery is an option for people who are severely obese and cannot lose weight by traditional means or who suffer from serious obesity-related health problems. The operation promotes weight loss and reduces the risk of type 2 diabetes by restricting food intake.

What is Bariatric Surgery?

Exercise and diet alone often fails to effectively treat people with extreme and excessive obesity. Bariatric surgery is an operation that is performed in order to help such individuals lose weight. Evidence suggests that bariatric surgery may lower death rates for patients with severe obesity, especially when coupled with healthy eating and lifestyle changes after surgery.

Bariatric Surgery Side Effects

Bariatric Surgery Types

Diet After Bariatric Surgery

Weight Loss After Bariatric Surgery

Taste Changes Following Bariatric Surgery

Metabolic Syndrome and Bariatric Surgery

Bariatric Surgery Research

Latest Bariatric Surgery News and Research

Study confirms bariatric surgery is safe and effective for patients with BMI over 70

A team of researchers led by Pennington Biomedical Research Center's Dr. Florina Corpodean confirmed through a data analysis that metabolic and bariatric surgery is largely safe and effective for patients who are experiencing severe obesity.

22 Nov 2024

Memories of obesity can linger in fat cells long after weight loss

Epigenetic changes from obesity persist after weight loss, altering fat cell function and increasing the risk of weight regain, impacting metabolic health.

19 Nov 2024

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

14 Nov 2024

Primary care clinicians key to achieving optimal cardiovascular health

Primary care clinicians and practices are uniquely positioned to help people achieve optimal cardiovascular health through screening, diagnosing and treating the health behaviors and factors outlined in the American Heart Association's Life's Essential 8 health metrics to reduce the risk for heart disease and stroke, according to a new scientific statement published today in the Association's peer-reviewed journal Circulation: Cardiovascular Quality and Outcomes.

13 Nov 2024

Adipo Therapeutics shares results of studies on potential obesity treatment

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the annual meeting of The Obesity Society in San Antonio.

7 Nov 2024

Weight loss drug semaglutide may offer relief for knee arthritis pain

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

4 Nov 2024

Long-term benefits of weight-loss surgery in young people with severe obesity

Young people with severe obesity who underwent weight-loss surgery at age 19 or younger continued to see sustained weight loss and resolution of common obesity-related comorbidities 10 years later, according to results from a large clinical study funded by the National Institutes of Health (NIH).

1 Nov 2024

New guidance balances GLP-1 risks and benefits for surgery

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical guidance released today by five surgical and medical societies including the American Society for Metabolic and Bariatric Surgery (ASMBS), American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), International Society of Perioperative Care of Patients with Obesity (ISPCOP), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

30 Oct 2024

Surge in GLP-1 drug use for obesity coincides with drop in bariatric surgery

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

26 Oct 2024

Low-carb diet may improve beta-cell function in type 2 diabetes patients

This study shows a carbohydrate-restricted diet boosts β-cell function in type 2 diabetes, offering a sustainable approach to manage the disease effectively.

24 Oct 2024

Scurvy may be making a comeback amid economic strain

The scourge of scurvy, which is caused by vitamin C deficiency, may be re-emerging amid the cost of living crisis and the rise in weight loss (bariatric) surgery, suggest doctors in the journal BMJ Case Reports after treating a middle-aged man with the condition.

22 Oct 2024

Cost-effectiveness of combining weight loss drugs and surgery

Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according to a study presented at the American College of Surgeons (ACS) Clinical Congress 2024 in San Francisco, California.

18 Oct 2024

GLP1R medications show promise in reducing suicidal ideation among adolescents with obesity

Adolescents treated with GLP1R drugs for obesity exhibit fewer suicidal thoughts, indicating potential mental health benefits of these medications.

17 Oct 2024

Weight-loss surgery may reduce pancreatic cancer risk in people with obesity

Obesity and type 2 diabetes are risk factors for various malignancies, including pancreatic cancer, which has a high death rate.

9 Oct 2024

Weekly injections of anti-obesity medications cost more than surgery

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) exceeds that of metabolic and bariatric surgery in less than a year, according to a recent analysis published in the journal Surgical Endoscopy.

7 Oct 2024

Bariatric surgery outperforms GLP-1 medications in protecting kidney function

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.

20 Sep 2024

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Researchers compare the weight loss efficacy of injectable liraglutide and semaglutide.

17 Sep 2024

Weight-loss surgery offers better control of high blood pressure compared to medications

People with obesity who underwent weight-loss surgery were more likely to control their high blood pressure over a 1-to-5 year follow-period compared to those who managed their high blood pressure with medications and lifestyle management, according to preliminary research to be presented at the American Heart Association's Hypertension Scientific Sessions 2024.

5 Sep 2024

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.

5 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024